Atea Pharmaceuticals, Inc. (AVIR)
NASDAQ: AVIR · Real-Time Price · USD
5.43
+0.07 (1.31%)
Aug 21, 2026, 4:00 PM EDT - Market closed
Atea Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 76.55 | 95.71 | 64.7 | 143.82 | 188.46 | 764.38 |
Short-Term Investments | 142.92 | 206.12 | 390.03 | 434.28 | 458.25 | - |
Cash & Short-Term Investments | 219.47 | 301.83 | 454.72 | 578.11 | 646.71 | 764.38 |
Cash Growth | -42.20% | -33.62% | -21.34% | -10.61% | -15.39% | -10.09% |
Other Receivables | - | - | - | 5.9 | - | - |
Receivables | - | - | - | 5.9 | - | - |
Prepaid Expenses | 9.2 | 9.16 | 7.63 | 6.45 | 14.21 | 8.03 |
Total Current Assets | 228.67 | 310.99 | 462.36 | 590.46 | 660.92 | 772.4 |
Property, Plant & Equipment | 0.57 | 1.09 | 2.12 | 3.12 | 4.09 | 0.18 |
Other Long-Term Assets | 3.05 | 3.14 | 0.2 | 1.4 | 1.69 | 0.31 |
Total Assets | 232.28 | 315.22 | 464.67 | 594.97 | 666.71 | 772.89 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 10.06 | 12.95 | 4.46 | 4.25 | 2.55 | 4.53 |
Accrued Expenses | 17.64 | 26 | 13.35 | 27.36 | 15.11 | 24.58 |
Current Portion of Leases | 0.42 | 0.84 | 0.8 | 0.76 | 0.72 | 0.2 |
Current Income Taxes Payable | - | - | - | - | 0.1 | 2.57 |
Other Current Liabilities | - | - | - | - | - | 25 |
Total Current Liabilities | 28.12 | 39.78 | 18.6 | 32.38 | 18.48 | 56.88 |
Long-Term Leases | - | - | 0.84 | 1.64 | 2.4 | - |
Other Long-Term Liabilities | - | - | 6.36 | 5.76 | 5.26 | 5.93 |
Total Liabilities | 28.12 | 39.78 | 25.8 | 39.78 | 26.14 | 62.82 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 |
Additional Paid-In Capital | 805.12 | 797.75 | 802.77 | 750.74 | 701.05 | 653.96 |
Retained Earnings | -600.94 | -522.57 | -364.22 | -195.84 | -59.88 | 56.03 |
Comprehensive Income & Other | -0.1 | 0.17 | 0.23 | 0.21 | -0.68 | - |
Total Common Equity | 204.16 | 275.43 | 438.87 | 555.19 | 640.57 | 710.08 |
Shareholders' Equity | 204.16 | 275.43 | 438.87 | 555.19 | 640.57 | 710.08 |
Total Liabilities & Equity | 232.28 | 315.22 | 464.67 | 594.97 | 666.71 | 772.89 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 0.42 | 0.84 | 1.64 | 2.4 | 3.12 | 0.2 |
Net Cash (Debt) | 219.04 | 300.99 | 453.08 | 575.7 | 643.59 | 764.18 |
Net Cash Growth | -42.12% | -33.57% | -21.30% | -10.55% | -15.78% | -10.11% |
Net Cash Per Share | 2.78 | 3.69 | 5.38 | 6.90 | 7.73 | 8.66 |
Filing Date Shares Outstanding | 80.2 | 79.67 | 85.53 | 84.16 | 83.34 | 83.23 |
Total Common Shares Outstanding | 80.2 | 78.13 | 84.46 | 83.44 | 83.29 | 83.1 |
Working Capital | 200.54 | 271.21 | 443.75 | 558.08 | 642.44 | 715.52 |
Book Value Per Share | 2.55 | 3.53 | 5.20 | 6.65 | 7.69 | 8.54 |
Tangible Book Value | 204.16 | 275.43 | 438.87 | 555.19 | 640.57 | 710.08 |
Tangible Book Value Per Share | 2.55 | 3.53 | 5.20 | 6.65 | 7.69 | 8.54 |
Machinery | - | 0.5 | 0.5 | 0.5 | 0.5 | 0.06 |
Leasehold Improvements | - | 1.48 | 1.48 | 1.48 | 1.48 | 0.13 |